Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, discusses the potential role of the STING pathway as a predictor of treatment outcomes in patients with colorectal cancer. The pathway is involved in interferon activation and analysis of data from two trials suggested the predicative nature of the STING pathway. Prof. Lenz additionally highlights a new generation of STING agonists under developments that are synergistic with immune checkpoint inhibitors. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.